A meta-analysis of erlotinib versus docetaxel for advanced nonsmall-cell lung cancer with poor prognosis

作者：Xu, W.; Jin, C.; Dai, X.; Lv, X.^*

来源：Indian Journal of Cancer, 2015, 52(5): E12-E16.

DOI：10.4103/0019-509X.168957

• Docetaxel
• erlotinib
• meta-analysis
• nonsmall-cell lung cancer

BACKGROUND: The extent of the benefit of erlotinib in the treatment of advanced nonsmall-cell lung cancer (NSCLC) is still controversial when compared with docetaxel. This meta-analysis was performed to compare the efficacy of erlotinib with docetaxel for different patients with advanced NSCLC. MATERIALS AND METHODS: We searched Cochrane Library, PubMed, CNKI, and identified 23 randomized controlled clinical trials from 2008 to 2015. According to our further full-text screening, 6 clinical trials were included in the final meta-analysis. RESULTS: Six papers were included in this study. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and toxicity were included in our outcomes. The pooled hazard ratio (HR) of PFS was 1.57 (95% confidential index [CI] = 1.47-1.69). The pooled HR of OS was 1.66 (95% CI = 1.43-1.92). The pooled risk ratio of ORR was 0.56 (95% CI = 0.35-0.91). The toxicity analysis showed odds ratio = 1.79 (95% CI = 1.20-2.69). CONCLUSIONS: In terms of PFS, OS, and toxicity the effect of erlotinib in the treatment of advanced NSCLC patients is superior to docetaxel.

• 出版日期2015-11
• 单位浙江大学